Episodes: 88
Frequency: Irregular
Rating: 4.1/5.0
Estimated listeners: <1k
Gender skew: Neutral
Location: United Kingdom
YouTube: 7.2k subscribers
Publicly listed emails
socialmedia@nice.org.uk
Looking for the right person? Join Podseeker to find direct host and producer contacts and manage your podcast outreach.
Amy Norman - Family Experience With Teplizumab Access And Outcomes
Lucy Chambers - Teplizumab Recommendation Impact And Patient/advocacy Perspective; Delaying Symptomatic Type 1 Diabetes
Emily Rose Jeffrey - Patient/family Experience Of NOAH Trial And Home-based Oral Antibiotic Care
Dr Harriet Aughey - Clinical Rationale And NOAH Project Perspective On Home Antibiotic Care
Dr Tim Watts - NICE Guideline Changes For Neonatal Infections And Shift To Home Oral Antibiotics
Second Chances: How new technology is transforming organ transplants
August 25, 2026
In this episode, we explore how new machine perfusion technology is changing the landscape of organ transplantation in the UK. NICE has published guidance recommending routine NHS access to specialist devices that keep donated livers and lungs functioning outside the body, potentially unlocking hundreds of organs for transplant each year. We hear from cardiothoracic surgeon Marius Berman, Clinical Director of the Transplant Programme at Royal Papworth Hospital. And by Monica Walsh, who recei...
PMOS: how the new draft NICE guideline could transform diagnosis and care
July 29, 2026
In this episode we explore the draft NICE guideline for PMOS (formerly known as PCOS), out for public consultation until 11 August 2026. We're joined by guideline committee members Aled Rees, professor of endocrinology at Cardiff University, and Sharon Manship, a lay member with lived experience of PMOS. Together they discuss how the recent name change, a new annual review, and a stronger focus on earlier diagnosis could transform care for the estimated 1 in 8 women living with the condition....
Changing the course: the NHS's first treatment to delay type 1 diabetes
June 30, 2026
NICE has recommended teplizumab for NHS use — the first treatment to delay the onset of symptomatic type 1 diabetes by an average of nearly three years. In this episode, we speak to Lucy Chambers, Head of Research Impact and Communications at Diabetes UK, and Amy Norman, whose daughter Imogen accessed teplizumab through a managed access programme after being identified through the ELSA screening study. Find out more: NICE recommendation for teplizumab: https://www.nice.org.uk/guidance/gid-...
Publicly listed emails
socialmedia@nice.org.uk
Looking for the right person? Join Podseeker to find direct host and producer contacts and manage your podcast outreach.
Try us risk free with a FREE 3 days trial.
Join hundreds of PR teams using Podseeker to pitch and land bookings